Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 11, 2022, the Board of Directors (the "Board") of AptarGroup, Inc. (the "Company") appointed Matthew L. Trerotola as a director effective as of such date. Mr. Trerotola will serve as a director for a term expiring at the Company's 2024 annual meeting of stockholders. The Board has determined that Mr. Trerotola is an "independent director" under New York Stock Exchange rules and has not yet determined any Board committee on which Mr. Trerotola will serve.

Mr. Trerotola, 55, has served as the President and Chief Executive Officer of Enovis Corporation (NYSE: ENOV) (formerly Colfax Corporation) ("Enovis"), an innovation-driven medical technology company, since 2015, and serves on the board of directors of Enovis. As a highly accomplished leader with over 30 years of experience, Mr. Trerotola has a distinct focus on accelerating organic growth as well as strategic acquisitions, margin and profitability improvements and talent development.

Mr. Trerotola's compensation for service on the Board will be consistent with that of other non-employee directors of the Company, as described in the Company's definitive proxy statement with respect to its 2022 annual meeting of stockholders filed with the Securities and Exchange Commission on March 25, 2022. There are no other arrangements or understandings between Mr. Trerotola and any other person pursuant to which he was appointed as director, and Mr. Trerotola is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K.

© Edgar Online, source Glimpses